Skip to main content
SpringerLink
Log in

Autologous and Allogeneic Transplantation for Multiple Myeloma

  • Chapter
Stem Cell Transplantation for Hematologic Malignancies

Part of the book series: Contemporary Hematology ((CH))

  • 145 Accesses

Abstract

The conventional treatment of myeloma frequently results in the achievement of a stable “plateau” phase during which patients have minimal or no symptoms related to their disease; however, during this phase, patients still have a considerable tumor burden. Conventional treatment with melphalan, melphalan and prednisolone, or combination chemotherapy regimens including cyclophosphamide, melphalan, carmustine (BCNU), lomustine (CCNU), adriamycin, vincristine, and prednisolone result in a median survival of between 24 and 36 mo, with approx 50% of patients responding to therapy. However, only a minority (5–10%) of patients attained a true complete remission (CR), with the disappearance of paraprotein and a normal marrow (1,2). Following the introduction of infusional chemotherapy, such as vincristine adriamucin dexamethasone (VAD), the number of patients responding to treatment (70–80%) and the level of response achieved increased, with CR rates of 8–28% (3,4). These responses were often short-lived, and it was with the purpose of improving the duration of response that high-dose therapy (HDT) was introduced (5).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. MacLennan IC, Chapman C, Dunn J, et al. Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. The Medical Research Council Working Party for Leukaemia in Adults. Lancet 1992; 25: 200–205.

    Article  Google Scholar 

  2. Myeloma Trialists Collaborative Group. Combination chemotherapy versus melphalan plus prednisolone as treatment for multiple myeloma: an overview of 6633 patients from 27 randomised trials. J Clin Oncol 1998; 16: 3832–3842.

    Google Scholar 

  3. Samson D, Gaminara E, Newland A, et al. Infusion of vincristine and doxorubicin with oral dexamethasone as first line therapy for multiple myeloma. Lancet 1989; 2: 882–885.

    Article  PubMed  CAS  Google Scholar 

  4. Raje N, Powles R, Kullarni S, et al. A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (C-VAMP) as induction treatment followed by autografting in previously untreated myeloma. Br J Haematol 1997; 97: 153–160.

    Article  PubMed  CAS  Google Scholar 

  5. McElwain TJ, Powles RL. High dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 1983;ii:822–824.

    Google Scholar 

  6. Gore ME, Selby PJ, Viner C, et al. Intensive treatment of multiple myeloma and criteria for complete remission. Lancet 1989; 2: 879–882.

    Article  PubMed  CAS  Google Scholar 

  7. Barlogie B, Jagannath S, Vesole DH, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997; 89: 789–793.

    PubMed  CAS  Google Scholar 

  8. Lenhoff S, Hjorth M, Holmberg E, et al. Impact on survival of high does therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population based study. Blood 2000; 95: 7–11.

    PubMed  CAS  Google Scholar 

  9. Blade J, San Miguel JF, Fontanillas M, et al. Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/autotransplantation and who are conventionally treated. J Clin Oncol 1996;7:21, 667–621, 673.

    Google Scholar 

  10. Attal M, Harousseau JL, Stoppa AM, et al. Autologous bone marrow transplantation versus conventional chemotherapy in multiple myeloma: a prospective randomised trial. N Eng J Med 1996; 335: 91–97.

    Article  CAS  Google Scholar 

  11. Child JA, Morgan GJ, Davies FE, et al. High dose therapy with hemotopoietic stem cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875–1883.

    Article  PubMed  CAS  Google Scholar 

  12. Fermand JP, Ravaud P, Katsahian S, et al. High dose therapy and autologous blood stem cell transplantation versus conventional treatment in multiple myeloma: results of a randomised trial in 190 patients 55–65 years of age. Blood 1999; 94: 396a.

    Google Scholar 

  13. Blade J, Sureda A, Ribera JM, et al. High dose therapy autotransplantation/intensification vs continued conventional chemotherapy in multiple myeloma patients responding to initial treatment chemotherapy. Results of a prospective randomised trial from the Spanish Cooperative Group PETHEMA. Blood 2001;98 [Abstract 3386].

    Google Scholar 

  14. Siegel DS, Desikan KR, Mehta J, et al. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 1999; 93: 51–54.

    PubMed  CAS  Google Scholar 

  15. Badros A, Barlogie B, Siegel E, et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001; 114: 822–829.

    Article  PubMed  CAS  Google Scholar 

  16. Sirohi B, Powles R, Mehta J, et al. The implication of comprised renal function at presentation in myeloma: similar outcome in patients who receive high-dose therapy: a single center study of 251 previously untreated patients. Med Oncol 2001; 18: 39–50.

    Article  PubMed  CAS  Google Scholar 

  17. Fermand JP, Ravaud P, Chevret S, et al. High dose therapy and autologous blood stem cell transplantation in multiple myeloma: up front or rescue treatment? Results of a multicenter sequential randomised clinical trial. Blood 1998; 92: 3131–3136.

    PubMed  CAS  Google Scholar 

  18. Barlogie B, Jagannath S, Desikan KR, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 55–65.

    PubMed  CAS  Google Scholar 

  19. Attal M, Harousseau IL, Facon T, for the IFM. Single versus double transplant in myeloma: a randomised trial of the Intergroupe Francais Myeloma. Proceedings of the VIII International Myeloma Workshop, 2001.

    Google Scholar 

  20. Fermand JP, Marolleau JP, Alberti C, et al. Single versus tandem high dose therapy supported with autologous blood stem cell transplantation using unselected or CD34 enriched AB SC: preliminary results of a two by two designed randomized trial in 230 young patients with multiple myeloma. Blood 2001; 98: 815a.

    Google Scholar 

  21. Cavo M. Tosi P, Zamagni E, et al. The Bologna 96 clinical trial of single vs double PBSCT transplantation for previously untreated MM: results of an interim analysis. Proceedings of the VIII International Myeloma Workshop, 2001.

    Google Scholar 

  22. Haroussseau JL, Attal M, Divine M, et al. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of French Registry on autologous transplantation in multiple myeloma. Blood 1995; 8: 3077–3085.

    Google Scholar 

  23. Moreau P, Facon T, Attal M, et al. Comparision of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the IFM 9502 randomised trial. Blood 2002; 99: 731–735.

    Article  PubMed  CAS  Google Scholar 

  24. Owen RG, Johnson RJ, Rawstron AC, et al. Assessment of IgH PCR strategies in multiple myeloma. J Clin Pathol 1996; 49: 672–675.

    Article  PubMed  CAS  Google Scholar 

  25. Corradini P, Voena C, Astolfi M, et al. High dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting. Blood 1995; 85: 1596–1602.

    PubMed  CAS  Google Scholar 

  26. Rawstron AC, Owen RG, Davies FE, et al. Circulating plasma cells in multiple myeloma: characterisation and correlation with disease stage. Br J Haematol 1997; 97: 46–55.

    Article  PubMed  CAS  Google Scholar 

  27. Johnson RJ, Owen RG, Smith GM, et al. Peripheral blood stem cell transplantation in myeloma using CD34 selected cells. Bone Marrow Transplant 1996; 17: 723–727.

    PubMed  CAS  Google Scholar 

  28. Vescio R, Schiller G, Stewart AK, et al. Multicentre phase III trial to evaluate CD34+ selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma. Blood 1999; 93: 1858–1868.

    PubMed  CAS  Google Scholar 

  29. Stewart AK, Vescio R, Schiller G, et al. Purging of autologous peripheral blood stem cells using cell selection does not improve overall or progression free survival after high dose chemotherapy for multiple myeloma: results of a multicenter randomised controlled trial. J Clin Oncol 2001; 19: 3771–3779.

    PubMed  CAS  Google Scholar 

  30. Facon T, Avet-Loiseau H, Guillerm G, et al. Chromosome 13 abnormalities identified by FISH analysis and serum B2 microglobulin produce a powerful myeloma staging system for patients receiving high dose therapy. Blood 2000; 97: 1566–1571.

    Article  Google Scholar 

  31. Lahuerta JJ, Martinez-Lopez J, Serna JD, et al. Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma. Br J Haematol 2000; 109: 438–446.

    Article  PubMed  CAS  Google Scholar 

  32. Davies FE, Forsyth PD, Rawstron AC, et al. The impact of attaining a minimal disease state following high dose melphalan and autologous transplantation for multiple myeloma. Br J Haematol 2001; 112: 814–820.

    Article  PubMed  CAS  Google Scholar 

  33. Corradini P, Voena C, Tarella C, et al. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoeitic cells. J Clin Oncol 1999; 17: 208–215.

    PubMed  CAS  Google Scholar 

  34. Martinelli G, Terragna C, Zamagni E, et al. Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. J Clin Oncol 2000; 18: 2273–2281.

    PubMed  CAS  Google Scholar 

  35. Rawstron AC, Davies FE, Dasgupta R, et al. Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome post-transplantation. Blood, 2002; 100: 3095–3100.

    Article  PubMed  CAS  Google Scholar 

  36. Gahrton G, Tura S, Ljungman P, et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 1995; 13: 1312–1322.

    PubMed  CAS  Google Scholar 

  37. Gahrton G, Svensson H, Cavo M, et al. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983–1993 and 19941998 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 2001; 113: 209–216.

    Article  PubMed  CAS  Google Scholar 

  38. Bensignger WI, Martin PJ, Storer B, et al. Transplantation of bone marrow as compared with peripheral blood cells from HLA identical relatives in patients with hematologic cancers. N Engl J Med 2001; 334: 175–181.

    Article  Google Scholar 

  39. Anderson KC. Plasma cell tumors. In: Cancer Medicine 5th ed. Bast R, Kufe D, Pollock R, Weichselbaum J, Holland J, Frei E, eds. New York: Marcel Dekker, 2000; 1257–1276.

    Google Scholar 

  40. Lokhorst HM, Schattenberg A, Cornelissen JJ, et al. Donor leucocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 1997; 90: 4206–4211.

    PubMed  CAS  Google Scholar 

  41. Alyea E, Weller E, Schlossman R, et al. T Cell depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft versus myeloma effect. Blood 2001; 98: 934–939.

    Article  PubMed  CAS  Google Scholar 

  42. Bensinger WI, Buckner CD, Anasetti C, et al. Allogeneic marrow transplantation for multiple myeloma: analysis of risk factors on outcome. Blood 1996; 88: 2787–2793.

    PubMed  CAS  Google Scholar 

  43. Storb R, Yu C, Sandmaier B, et al. Mixed hematopoietic chimersism after haematopoietic stem cell allografts. Transplant Proc 1999; 31: 677–678.

    Article  PubMed  CAS  Google Scholar 

  44. Badros A, Barlogie B, Siegel E, et al. Improved outcome of allogeneic transplantation in high risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol 2002; 20: 1295–1303.

    Article  PubMed  Google Scholar 

  45. Maloney DG, Sahebi F, Stockerl-Goldstein KE, et al. Combining an allogeneic graft vs myeloma effect with high dose autologous stem cell rescue in the treatment of multiple myeoma. Blood 2001; 98: 434a.

    Google Scholar 

  46. Kroger N, Schwerdtfeger R, Kiehl M, et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 2002; 100: 755–760.

    Article  PubMed  CAS  Google Scholar 

  47. The Myeloma Trialists Collaborative Group. Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol 2001; 113: 1020–1034.

    Article  Google Scholar 

  48. Berenson 7R, Crowley 77, Grogan TM, et al. Maintenance therapy with alternative-day prednisone improves survival in multiple myeloma patients. Blood 2002; 99: 3163–3168.

    Article  Google Scholar 

Download references

Authors
  1. Faith E. Davies MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kenneth C. Anderson MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

    Robert J. Soiffer MD

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer Science+Business Media New York

About this chapter

Cite this chapter

Davies, F.E., Anderson, K.C. (2004). Autologous and Allogeneic Transplantation for Multiple Myeloma. In: Soiffer, R.J. (eds) Stem Cell Transplantation for Hematologic Malignancies. Contemporary Hematology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-733-8_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-733-8_4

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4757-6588-5

  • Online ISBN: 978-1-59259-733-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation